This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19. Briefly, 50 patients with COVID-19 and respiratory failure who meet eligibility criteria and agree to participation in the study will be placed on losartan 25 mg daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria (detailed below) or complete 14 days of therapy. Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group. We will also collect medical information relating to safety criteria on historical controls treated at the University of Kansas Hospital in the 30 days prior to the study start date (3/25/2020) and during the study period.
This is an open label, phase 1 clinical trial to evaluate the safety of losartan in
respiratory failure due to COVID-19.
Clinical Trial setup:
Detailed inclusion and exclusion criteria are listed below. Briefly, 50 patients with
COVID-19 and respiratory failure who meet criteria and agree to participation in the study
will be placed on losartan 25 mg daily on study day 0. If parameters are met the dose of
losartan will be increased to 50 mg once daily on study day 3. Participants will continue
losartan until they experience resolution of respiratory failure (normal oxygen levels on
room air), are discharged from the hospital, meet stoppage criteria (detailed below) or
complete 14 days of therapy.
Patients and/or surrogate decision maker who do not give consent to treatment will be asked
to allow collection of data from their medical record for use as a control group.
Stoppage criteria for losartan
- Hyperkalemia (persistent values >5.5 mM recorded on at least 2 readings).
- Worsening renal function (Cockcroft-Gault <30 mL/min/1.73 m2) or urinary output <20
mL/h.
- Skin rashes, palpitations or other moderate or severe adverse events (interference with
usual daily activities) without clear explanation should warrant immediate cessation of
treatment and notification of study personnel.
- Development of sustained hypotension defined as SBP <90 mmHg, DBP <60 mmHg recorded on
at least two readings 30 min apart or use of norepinephrine >0.1 µg/kg/min.
- Any change in monitor lab parameters deemed significant and potentially related to study
drug by the Investigator.
Drug: Losartan
25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
Other Name: Cozaar
Inclusion Criteria:
- Age >18 years admitted to the University of Kansas Health System.
- Confirmation of infection with SARS-CoV-2 by PCR testing.
- Hypoxic respiratory failure Requiring mechanical ventilation or oxygen OR a SpO2 ≤94%
on room air or a PaO2/FiO2 (P/F) ratio <300 OR tachypnea (respiratory rate ≥24
breaths/min). Criteria to be met within 48 hours prior to Day 0.
- Other concomitant medications such as antivirals and hydroxychloroquine are allowed.
- Participants prescribed standard of care (SOC) losartan (25mg QD) within 48 hours of
consenting may be considered for enrollment if eligibility criteria are met based on
EMR data assessment, i.e. no other ARB or ACE prior to SOC medication administration.
If participant is eligible and signs consent form, investigational losartan 25mg QD
will be ordered to replace SOC prescription on the following scheduled dose.
Exclusion Criteria:
- Pregnancy.
- Respiratory failure due to a process other than COVID-19.
- Intolerance to ARBs.
- Previous treatment with an ARB or ACE inhibitor (see exception in inclusion criteria).
- Current chronic use of medication with known interactions with losartan including
NSAIDs (intermittent prior use is acceptable), potassium supplementation aliskiren.
- Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic recorded on at least
two readings 30 min apart.
- Need for vasopressors, unless norepinephrine ≤0.1 µg/kg/min
- Hyperkalemia (serum K+ >5.5 mM).
- Known cardiac failure (left ventricular ejection fraction ≤35%), renal insufficiency
(Cockcroft-Gault <30 mL/min/1.73 m2 or urinary output <20 mL/h), hepatic failure (LFTs
> 5x normal upper limit).
- Known renal artery stenosis.
- Neurological, psychiatric, endocrine or neoplastic diseases that are judged to
interfere with participation in the study.
- On another interventional trial (including one for COVID-19) that excludes
participation.
University of Kansas Medical Center
Kansas City, Kansas, United States
Matthias Salathe, Principal Investigator
University of Kansas Medical Center